Lung Cancer News and Research

Latest Lung Cancer News and Research

Disrupted micronuclei might play more active role in carcinogenesis, new study finds

Scientists studying cancer development have known about micronuclei for some time. These erratic, small extra nuclei, which contain fragments or whole chromosomes that were not incorporated into daughter cells after cell division, are associated with specific forms of cancer and are predictive of poorer prognosis.

9 Jul 2013

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Imaging techniques in cancer medicine provide far more than merely information on the scale and location of cancerous ulcers. There are modern methods that additionally characterise the tumour cells precisely, for instance by specific molecules they carry on their surface. Such additional information gives doctors key clues as to the precise cancer type and enables them to predict the probability that a patient will respond to a particular form of therapy.

6 Jul 2013

Scientists focus on the role of mutated adult neural stem cells play in human diseases

CHARGE syndrome* is a severe developmental disorder affecting multiple organs. It affects 1 in 8500 newborns worldwide. The majority of patients carry a mutation in a gene called CHD7. How this single mutation leads to the broad spectrum of characteristic CHARGE symptoms has been a mystery.

6 Jul 2013

NIDA grants $3.3M to design vaccine conferring immunity to nicotine

A chemical component present in the nightshade family of plants is one of the world's most tenaciously addictive substances. It is the nicotine contained in tobacco and found in high concentrations in cigarettes. Smoking remains a global scourge; in the U.S. it is the leading source of preventable death.

3 Jul 2013

Researchers find NRF2 signaling plays a role in growth of tumor cells by altering metabolic pathways

Cancer cells have alteration in metabolic pathways as a result of oncogenes that promote tumor growth. NRF2 (nuclear factor erythroid-derived 2-related factor 2) works as a "master gene" that turns on stress response by increasing numerous antioxidants and pollutant-detoxifying genes to protect the lungs from variety of air pollutants such as diesel exhaust and cigarette smoke.

3 Jul 2013

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Array BioPharma Inc. announced today that a $5 million milestone was achieved after the start of Array's Phase 3 clinical trial in patients with low-grade serous ovarian cancer.

2 Jul 2013

First Edition: July 2, 2013

Today's headlines include various reports about changes afoot in the insurance marketplace.

2 Jul 2013

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

ARIAD Pharmaceuticals, Inc. today announced that the European Commission has granted a marketing authorization for Iclusig (ponatinib) as an orphan medicinal product for two indications.

2 Jul 2013

Research roundup: 'Welcome-mat' effect of Medicaid expansion; Setting up shops; California's transition to Medicaid managed care

The number of people eligible for Medicaid who remain uninsured varies from state to state, according to the authors. But the federal health law is likely to increase the rate of enrollment for this group. The potential impact of this increase in Medicaid enrollment, also known as the 'welcome-mat' effect, is unclear.

2 Jul 2013

ALK immunocytochemistry accurately detects NSCLC on cytological specimens

Personalized medicine in lung cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers.

2 Jul 2013

Researchers use two new methods to detect levels of ALK protein expression in NSCLC

The implementation of personalized health care in cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers.

2 Jul 2013

SBRT treatment safe and effective for stage I NSCLC, study finds

Stereotactic body radiotherapy is considered the treatment of choice for early-stage non-small-cell lung cancer if patients are inoperable because of additional medical conditions.

2 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Study shows autophagy blockers play a role in treatment of non-small-cell lung cancer

New research from Rutgers Cancer Institute of New Jersey, Princeton University and other collaborators suggests that inactivation of an essential gene responsible for the cell survival process known as autophagy can suppress the growth of non-small-cell lung cancer tumors and render them more benign.

1 Jul 2013

Case Comprehensive Cancer Center secures "outstanding" rating from NCI

The Case Comprehensive Cancer Center (CCCC) again demonstrated the compelling power of partnership in securing an overall rating of "outstanding" and a five-year renewal of its grant from the National Cancer Institute (NCI).

28 Jun 2013

Low-molecular-weight PAHs promote conditions for cancer growth

Tobacco smoke, diesel exhaust and oil combustion carry polycyclic aromatic hydrocarbons - PAHs that are known to cause cancer. But of these PAHs, the obviously dangerous high-molecular-weight PAHs like benzo[a]pyrene (BaP) have received the vast majority of research attention.

26 Jun 2013

Immunohistochemistry could be a reliable and cost-effective diagnostic approach for lung cancer

ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (NSCLC). It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma that can benefit by the treatment of ALK-inhibitors.

26 Jun 2013

Pretreatment PET staging of LS-SCLC associated with improved survival

Each year, 13 percent of all newly diagnosed lung cancer patients are diagnosed with small-cell lung cancer (SCLC). Approximately 39 percent of patients with SCLC are diagnosed with limited-stage disease, meaning the cancer is only present in one lung, but may have spread to lymph nodes or tissue between the lungs.

26 Jun 2013

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened enrollment in a Phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies.

26 Jun 2013

Lung cancer in women more frequently associated with EGFR mutation and ER expression

The incidence of lung cancer in women affects an estimated 516,000 women worldwide, of which 100,000 are in the United States and 70,000 in Europe. Until now, lung cancers occurring in women have been treated similarly to lung cancers in men. However, numerous studies have highlighted different characteristics of lung cancer in women.

26 Jun 2013

Lung Cancer News and Research

Latest Lung Cancer News and Research

Disrupted micronuclei might play more active role in carcinogenesis, new study finds

Researchers develop new PET tracer to better monitor the progress of cancer and cancer therapy

Scientists focus on the role of mutated adult neural stem cells play in human diseases

NIDA grants $3.3M to design vaccine conferring immunity to nicotine

Researchers find NRF2 signaling plays a role in growth of tumor cells by altering metabolic pathways

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

First Edition: July 2, 2013

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

Research roundup: 'Welcome-mat' effect of Medicaid expansion; Setting up shops; California's transition to Medicaid managed care

ALK immunocytochemistry accurately detects NSCLC on cytological specimens

Researchers use two new methods to detect levels of ALK protein expression in NSCLC

SBRT treatment safe and effective for stage I NSCLC, study finds

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Study shows autophagy blockers play a role in treatment of non-small-cell lung cancer

Case Comprehensive Cancer Center secures "outstanding" rating from NCI

Low-molecular-weight PAHs promote conditions for cancer growth

Immunohistochemistry could be a reliable and cost-effective diagnostic approach for lung cancer

Pretreatment PET staging of LS-SCLC associated with improved survival

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Lung cancer in women more frequently associated with EGFR mutation and ER expression

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in